

## Special Issue

# Early Detection and Diagnosis of Pancreatic Cancer

### Message from the Guest Editor

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer deaths in Western countries and one of the most lethal of the common cancers. The disease is almost always detected at an advanced stage. This makes curative interventions difficult and contributes to the extremely poor 5-year survival rate of 3% to 15%. The late detection of PDAC can be attributed to a number of factors, including complex underlying biology, vague symptoms which overlap with a variety of benign diseases, a lack of biomarkers that are validated for early detection, and the absence of imaging techniques that can detect precancerous lesions with accuracy. While screening is recommended in high-risk groups, the fact that PDAC is relatively uncommon and that accurate detection tests are not available means that screening of asymptomatic individuals in the general population is not feasible. It is recognized that early cancer detection reduces mortality, and currently, there is a wave of interest in finding ways to detect PDAC earlier. This Special Issue will highlight recent progress with regard to high-risk groups, biomarker development, as well as advances in imaging and prediction modeling.

---

### Deadline for manuscript submissions

closed (30 September 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/68515](https://mdpi.com/si/68515)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)